Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

The collaboration aims to advance the discovery and development of novel oral candidates.

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca said it entered into a strategic research collaboration with China's CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

(Alliance News) - AstraZeneca PLC on Friday reported an AI-focused collaboration with Shijiazhuang City, China-based CSPC Pharmaceutical Group Ltd, boosting its existing presence in the country.